Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Incyte Corp INCY

Healthcare Biotechnology
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is... see more

Recent & Breaking News (NDAQ:INCY)

Incyte to Present at Upcoming Investor Conferences

Business Wire May 24, 2018

Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings

Benzinga.com  May 2, 2018

Incyte Reports 2018 First-Quarter Financial Results and Updates on Key Clinical Programs

Business Wire May 1, 2018

Incyte to Present at Upcoming Investor Conference

Business Wire April 26, 2018

Incyte Highlights Abstracts Accepted for Presentation at the 2018 ASCO Annual Meeting

Business Wire April 25, 2018

38 Biggest Movers From Yesterday

Benzinga.com  April 25, 2018

FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis

PR Newswire April 23, 2018

The Week Ahead: Sohn Conference, FANG Earnings, DocuSign IPO

Benzinga.com  April 23, 2018

The Week Ahead In Biotech: PDUFA Dates, IPOs And More

Benzinga.com  April 20, 2018

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Incyte Corporation (INCY)

PR Newswire April 20, 2018

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Incyte Corporation - INCY

PR Newswire April 19, 2018

Incyte to Report First Quarter Financial Results

Business Wire April 13, 2018

30 Biggest Movers From Friday

Benzinga.com  April 9, 2018

Mid-Afternoon Market Update: Crude Oil Down 2%; PriceSmart Shares Spike Higher

Benzinga.com  April 6, 2018

Mid-Day Market Update: Dow Falls 350 Points; Incyte Shares Plunge

Benzinga.com  April 6, 2018

Incyte Falls 20% After Cancer Drug Fails Phase 3 Trial

Benzinga.com  April 6, 2018

Incyte and Merck Provide Update on Phase 3 Study of Epacadostat in Combination with KEYTRUDA® (pembrolizumab) in Patients with Unresectable or Metastatic Melanoma

Business Wire April 6, 2018

Incyte Targeted Therapy and Immuno-Oncology Portfolio to be Featured in 15 Abstracts at the AACR Annual Meeting 2018

Business Wire March 15, 2018

Report: Exploring Fundamental Drivers Behind Old Republic International, NiSource, MasTec, Lincoln National, Oceaneering International, and Incyte — New Horizons, Emerging Trends, and Upcoming Developments

GlobeNewswire March 8, 2018

Incyte Supports the Myeloproliferative Neoplasm Community in Honor of Rare Disease Day 2018

Business Wire February 28, 2018